| DB ID | MyCo_2554 |
| Title | Bronchoalveolar Lavage Fluid (1,3)β-D-Glucan for the Diagnosis of Invasive Fungal Infections in Solid Organ Transplantation: A Prospective Multicenter Study |
| Year | 2015 |
| PMID | 25710608 |
| Fungal Diseases involved | Invasive aspergillosis |
| Associated Medical Condition | Solid Organ Transplantation Patients |
| Genus | Aspergillus |
| Species | fumigatus |
| Organism | Aspergillus fumigatus |
| Ethical Statement | The study protocol was approved by the Institutional Review Board at the respective center (Innsbruck: UN4202, Graz: 23–243 ex10/11 and Vienna: 380/2011). The intended use of the BG test of BALs was reported to the Austrian Agency for Health and Food Safety (protocol number INS-621000-0222). |
| Site of Infection | None |
| Opportunistic invasive | None |
| Sample type | Body fluid |
| Sample source | Bronchoalveolar lavage fluid (BALF) |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | GM |
| Biomarker Full Name | Galactomannan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Austria |
| Cohort | Bronchoalveolar lavage and sera from SOT patients with clinical and radiological suspicion of IFI were collected during the study period (April 2012 to July 2013) in 4 different clinical sites in Austria. The University Hospitals of Innsbruck, Graz, and Vienna and the Hospital of Natters participated in this multicenter study. Adult patients (≥18 years of age) who underwent a bronchoscopy with lavage for diagnostic purposes of fungal lung infections were investigated. A total of 233 BALs and 109 sera from 135 nonselected SOT patients were included in this prospective, multicenter, noninterventional cross-over study; the underlying population consisted of 71 men and 64 women, and the median age was 53 years (interquartile range [IQR], 37–62). |
| Cohort No. | 135 |
| Age Group | 37-62 |
| P Value | None |
| Sensitivity | 0.815 |
| Specificity | 0.952 |
| Positive Predictive Value | 0.733 |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Invasive fungal diseases (IFDs) are life-threatening infections in patients with hemato oncological malignancies and solid-organ transplant (SOT) recipients. The Transplant- Associated Infection Surveillance Network recently reported the 1-year cumulative incidence of invasive fungal infections (IFIs) in SOT patients to be 8.6%.1,2 The same study reported that clinical outcome in patients with IFI largely depends on a timely diagnosis of the infection and that clinical trials indicate a strong correlation of survival with early antifungal treatment.1,2 The most important pathogens identified are Aspergillus species, Candida species, and non-Aspergillus molds. |
| Technique | Immunological assay |
| Analysis Method | ELISA Based |
| ELISA kits | None |
| Assay Data | FDA- Fungitell®, Cape Cod International, Inc.; Falmounth, MA, USA |
| Validation Techniques used | GM-Platelia Aspergillus Ag Immunoassay |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
